title: Effect of fenoterol stereochemistry on the β2 adrenergic receptor system: ligand-directed chiral recognition.
abstract: The β(2) adrenergic receptor (β(2)-AR) is a model system for studying the ligand recognition process in G protein-coupled receptors. Fenoterol (FEN) is a β(2)-AR selective agonist that has two centers of chirality and exists as four stereoisomers. Radioligand binding studies determined that stereochemistry greatly influences the binding affinity. Subsequent Van't Hoff analysis shows very different thermodynamics of binding depending on the stereoconfiguration of the molecule. The binding of (S,x')-isomers is almost entirely enthalpy controlled whereas binding of (R,x')-isomers is purely entropy driven. Stereochemistry of FEN molecule also affects the coupling of the receptor to different G proteins. In a rat cardiomyocyte contractility model, (R,R')-FEN was shown to selectively activate G(s) protein signaling while the (S,R')-isomer activated both G(i) and G(s) protein. The overall data demonstrate that the chirality at the two chiral centers of the FEN molecule influences the magnitude of binding affinity, thermodynamics of local interactions within the binding site, and the global mechanism of β(2)-AR activation. Differences in thermodynamic parameters and nonuniform G-protein coupling suggest a mechanism of chiral recognition in which observed enantioselectivities arise from the interaction of the (R,x')-FEN stereoisomers with a different receptor conformation than the one with which the (S,x')-isomer interacts.
authors: Laboratory of Medicinal Chemistry and Neuroengineering, Medical University of Lublin, Lublin, Poland. krzysztof.jozwiak@umlub.pl
authors: Krzysztof
authors: K
authors: Jozwiak
authors: Anita
authors: A
authors: Plazinska
authors: Lawrence
authors: L
authors: Toll
authors: Lucita
authors: L
authors: Jimenez
authors: Anthony Yiu-Ho
authors: AY
authors: Woo
authors: Rui-Ping
authors: RP
authors: Xiao
authors: Irving W
authors: IW
authors: Wainer
references: Biochem Pharmacol. 2010 Jun 1;79(11):1610-5
references: 20144591
references: J Am Chem Soc. 2010 Aug 25;132(33):11443-5
references: 20669948
references: Bioorg Med Chem. 2010 Jan 15;18(2):728-36
references: 20036561
references: Naunyn Schmiedebergs Arch Pharmacol. 1978 Oct;305(1):41-50
references: 214719
references: Chirality. 2006 Nov;18(10):822-7
references: 16917835
references: Science. 2007 Nov 23;318(5854):1258-65
references: 17962520
references: Nature. 2011 Jan 13;469(7329):175-80
references: 21228869
references: Science. 1986 May 30;232(4754):1132-5
references: 3704640
references: Nature. 2010 Jan 7;463(7277):108-12
references: 20054398
references: Chirality. 2008 Mar;20(3-4):529-43
references: 18172836
references: Biochim Biophys Acta. 2007 Apr;1768(4):794-807
references: 17188232
references: Mol Pharmacol. 1995 Feb;47(2):322-9
references: 7870040
references: Mol Pharmacol. 2009 Jan;75(1):158-65
references: 18838481
references: Nature. 2000 Feb 10;403(6770):614-5
references: 10688187
references: Mol Pharmacol. 2009 Jan;75(1):13-8
references: 19001067
references: J Pharmacol Exp Ther. 2011 Feb;336(2):524-32
references: 21071556
references: Methods Mol Biol. 2009;552:67-77
references: 19513642
references: J Pharmacol Exp Ther. 2008 Dec;327(3):760-9
references: 18772317
references: J Med Chem. 2007 Jun 14;50(12):2903-15
references: 17506540
references: Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9276-81
references: 8799191
references: Bioorg Med Chem Lett. 2007 Jul 15;17(14):4012-5
references: 17498952
references: J Pharm Pharmacol. 1972 Apr;24(4):277-80
references: 4402834